Navigation Links
This week in Blood: Jan. 10, 2013
Date:1/10/2013

Welcome to "This Week in Blood," a weekly snapshot of the hottest studies from each week's issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Lwenberg, MD, and Deputy Editor Nancy Berliner, MD.

Systemic delivery of a TLR7 agonist in combination with radiation primes durable anti-tumor immune responses in mouse models of lymphoma, Dovedi et al.

This week's plenary paper offers a promising potential new immunotherapeutic modality for the treatment of lymphoma. The authors present convincing data to suggest that a toll-like receptor 7 (TLR7) agonist sensitizes tumor cells to radiotherapy. In a mouse model, this increases radiation-induced cell death and prolongs responses.

Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia, Horn et al.

The success of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (CML) has led to early investigation of the safety of discontinuing therapy for patients with prolonged deep response to treatment. In this manuscript, Horn and colleagues present a way of predicting the safety of therapy discontinuation.

Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms, Cazzola et al.

This manuscript, featured as this week's Perspective, discusses how our understanding of the pathophysiology of myelodysplastic syndromes (MDS) and other hematologic malignancies has been transformed over the last year with the discovery of the prevalence and prognostic significance of mutations in genes encoding the cellular splicing machinery.


'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. Patient Survival Rises When Drugs Suppress Hepatitis C in Blood: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
Breaking Medicine Technology: